Top 10 Biotech Companies in New York to Watch Leading Into 2026
New York’s biotech ecosystem has matured rapidly—driven by academic excellence, strong translational research, and growing venture investment. As we head into 2026, here are ten New York–headquartered biotech companies shaping the future of life sciences.
Why New York’s biotech ecosystem matters in 2026
Historically overshadowed by Boston and the Bay Area, New York has emerged as a serious biotech hub. Anchored by world-class institutions (Columbia, NYU, Mount Sinai, Rockefeller University), major health systems, and increasing public-private investment, New York biotech companies are translating academic research into commercial therapeutics faster than ever.
What makes New York distinctive is its emphasis on translational medicine, cell and gene therapies, and AI-driven discovery—often tightly integrated with clinical environments.
Top 10 biotech companies in New York to watch
Each profile includes headquarters location, company focus, and why it matters heading into 2026.
1. Regeneron Pharmaceuticals
Website: regeneron.com
Founded: 1988
Size: ~14,000 employees
Headquartered in Tarrytown, NY, Regeneron is one of the most successful biotech companies globally. With a strong pipeline across immunology, oncology, and rare diseases—and deep investments in genetics-driven discovery—Regeneron continues to set the benchmark for scalable biotech innovation going into 2026.
2. Schrödinger
Website: schrodinger.com
Founded: 1990
Size: ~800 employees
Schrödinger applies physics-based modeling and machine learning to drug discovery. Based in New York City, the company sits at the intersection of biotech and computational science—an increasingly important position as AI-driven discovery accelerates.
3. BridgeBio Pharma (New York operations)
Website: bridgebio.com
Founded: 2015
Size: ~1,000 employees
BridgeBio maintains significant operations in New York, focusing on genetic diseases with high unmet need. Its hub-and-spoke model and translational focus make it a key player as precision medicine programs advance into later stages.
4. Evotec (US East Coast HQ – New York)
Website: evotec.com
Founded: 1993
Size: ~4,500 employees globally
Evotec’s New York presence supports its growing role as a discovery and development partner for biotech and pharma companies. Its platform-based approach to R&D execution aligns closely with how modern biotech pipelines are scaling.
5. Celmatix
Website: celmatix.com
Founded: 2009
Size: ~100 employees
Celmatix focuses on reproductive health and ovarian biology, combining data science with clinical insights. As women’s health becomes a major biotech investment area, Celmatix is positioned for increased visibility into 2026.
6. AiCure
Website: aicure.com
Founded: 2010
Size: ~200 employees
AiCure uses AI to improve clinical trial execution and patient adherence. Based in New York City, the company reflects the city’s strength in applying AI and analytics to clinical-stage biotech challenges.
7. Excision BioTherapeutics
Website: excisionbio.com
Founded: 2015
Size: ~100 employees
Excision BioTherapeutics is developing CRISPR-based therapies for viral infectious diseases. Its New York base and translational focus place it at the forefront of gene-editing innovation as these therapies mature.
8. Kallyope
Website: kallyope.com
Founded: 2015
Size: ~150 employees
Kallyope is advancing therapies targeting the gut-brain axis. Its science-driven approach and ties to leading academic research highlight New York’s growing role in neuroscience and metabolic disease innovation.
9. EpiVario
Website: epivario.com
Founded: 2018
Size: Startup
EpiVario focuses on single-cell epigenetic profiling. As cell-level resolution becomes increasingly important in drug discovery, companies like EpiVario represent the next wave of enabling biotech platforms.
10. Volastra Therapeutics
Website: volastratx.com
Founded: 2019
Size: ~100 employees
Volastra Therapeutics is developing cancer therapies targeting chromosomal instability. Its translational oncology focus aligns with New York’s strength in bridging academic research and clinical application.
What New York biotech signals for 2026
- Translational strength: Tight integration between research and clinical environments
- AI and computation: Growing role of modeling, simulation, and data science
- Cell and gene therapy momentum: Continued investment in next-generation modalities
- Execution at scale: Increasing need for operational systems that support complex R&D workflows
